Cytopathic effect of in situ gene therapy in prostate cancer

被引:29
作者
Ayala, G
Wheeler, TM
Shalev, M
Thompson, TC
Miles, B
Aguilar-Cordova, E
Chakraborty, S
Kadmon, D
机构
[1] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[2] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Pediat, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
关键词
prostate cancer; gene therapy; morphology;
D O I
10.1053/hupa.2000.8453
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This is a morphologic study of in situ gene therapy effects in patients with prostate cancer using the Herpes Simplex Virus-Thymidine Kinase gene (HSV-tk) followed by ganciclovir. Prostatectomy specimens from the first 4 patients showed the following morphologic changes: (1) various degrees of necrosis were seen in cancer foci; (2) cytopathic changes were seen across the whole spectrum of Gleason grades; (3) the normal prostate was rarely affected by necrosis, but contained an intense mononuclear infiltrate; (4) loss of nuclear detail was a common finding. Volumetric studies showed that only portions of the tumor show morphologic effects as well as an inverse relationship between percentage of affected tumor and prostate and tumor size. An inflammatory response was observed, with predominance of CD20-positive cells in normal prostate tissue, CD8 (cytotoxic T cells) in the tumor, and macrophages in all areas of the treated prostates. We believe that these changes represent the cytopathic effect of our in situ gene therapy on prostate cancer, and that they trigger a local immune response. Copyright (C) 2000 by W.B. Saunders Company.
引用
收藏
页码:866 / 870
页数:5
相关论文
共 16 条
  • [1] HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA IN PROSTATES REMOVED FOLLOWING IRRADIATION FAILURE IN THE TREATMENT OF PROSTATIC ADENOCARCINOMA
    ARAKAWA, A
    SONG, S
    SCARDINO, PT
    WHEELER, TM
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 1995, 191 (09) : 868 - 872
  • [2] RADIATION-INJURY OF THE NORMAL AND NEOPLASTIC PROSTATE
    BOSTWICK, DG
    EGBERT, BM
    FAJARDO, LF
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1982, 6 (06) : 541 - 551
  • [3] Civantos F, 1996, Semin Urol Oncol, V14, P22
  • [4] CIVANTOS F, 1995, CANCER, V75, P1634, DOI 10.1002/1097-0142(19950401)75:7<1634::AID-CNCR2820750713>3.0.CO
  • [5] 2-#
  • [6] Hall SJ, 1997, INT J CANCER, V70, P183, DOI 10.1002/(SICI)1097-0215(19970117)70:2<183::AID-IJC8>3.0.CO
  • [7] 2-T
  • [8] HISTOLOGICAL AND IMMUNOHISTOCHEMICAL FINDINGS OF PROSTATIC-CARCINOMA AFTER EXTERNAL OR INTERSTITIAL RADIOTHERAPY
    HELPAP, B
    KOCH, V
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1991, 117 (06) : 608 - 614
  • [9] In situ gene therapy for adenocarcinoma of the prostate:: A phase I clinical trial
    Herman, JR
    Adler, HL
    Aguilar-Cordova, E
    Rojas-Martinez, A
    Woo, S
    Timme, TL
    Wheeler, TM
    Thompson, TC
    Scardino, PT
    [J]. HUMAN GENE THERAPY, 1999, 10 (07) : 1239 - 1249
  • [10] Pathological changes in prostate lesions after androgen manipulation
    Montironi, R
    Schulman, CC
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1998, 51 (01) : 5 - 12